New MHRA service expected to accelerate medicines innovation
by Harriet Belderbos · Open Access GovernmentThe Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new initiative designed to help innovative medicines reach patients sooner
The new service, named AdvanceGxP, will provide developers with earlier, practical regulatory and quality support as they develop new technologies and approaches to medicines manufacturing. The aim is to identify potential challenges earlier in the development process, helping companies avoid unnecessary redesigns, reduce delays and bring new treatments to patients more quickly.
Supporting next-generation medicines manufacturing
AdvanceGxP will initially focus on advanced manufacturing technologies, including personalised medicines produced at or near hospitals and clinics, manufacturing in space, and the growing use of artificial intelligence (AI), robotics and automation.
As these technologies develop, manufacturers face new questions about how existing Good Practice (GxP) standards and regulatory requirements should be applied. The new service will give innovators earlier access to specialist MHRA expertise, helping them understand regulatory expectations and address potential quality issues before they become significant obstacles.
Government funding to develop the service
The MHRA has secured funding from the Office for Life Sciences (OLS) to develop and test AdvanceGxP. The initiative was announced by Science, Innovation and Investment Minister Chris McDonald MP during his closing keynote at the inaugural DIA-MHRA Global Summit in London on 17 November 2026.
The funding will allow the MHRA to recruit a specialist team and establish how the service will operate. This includes determining how organisations can access support, which technologies and projects will be prioritised, and how the initiative will work alongside existing regulatory services.
Initially, capacity will be limited while the MHRA tests the approach and assesses how it can be delivered sustainably. The findings will help determine whether the service could be expanded to support a wider range of technologies and projects in the future.
Supporting the UK’s life sciences ambitions
AdvanceGxP supports MHRA’s Strategy to 2030, which places greater emphasis on early engagement and closer collaboration across the health and life sciences sectors.
By helping innovative technologies navigate regulatory requirements more effectively, AdvanceGxP aims to create an environment where new medicines can be developed and manufactured in the UK, supporting future investment, economic growth and improved access to innovative treatments for patients.